LDE-225 (Erismodegib/Sonidegib/Odomzo), a Cyclopamine derivative, effectively induces cell cycle arrest and apoptosis across various cancers, including GBM, by antagonising SMO and reducing GLI protein expression, validated in mouse models [136–138]. Here, GLI1 is linked to cancer.